Pflug Koory LLC Sells 400 Shares of Abbott Laboratories (NYSE:ABT)

Share on StockTwits

Pflug Koory LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 2.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,674 shares of the healthcare product maker’s stock after selling 400 shares during the quarter. Pflug Koory LLC’s holdings in Abbott Laboratories were worth $1,188,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Appleton Partners Inc. MA lifted its stake in shares of Abbott Laboratories by 0.5% during the 3rd quarter. Appleton Partners Inc. MA now owns 24,589 shares of the healthcare product maker’s stock valued at $2,057,000 after buying an additional 123 shares in the last quarter. Circle Wealth Management LLC lifted its stake in shares of Abbott Laboratories by 3.8% during the 3rd quarter. Circle Wealth Management LLC now owns 3,468 shares of the healthcare product maker’s stock valued at $290,000 after buying an additional 126 shares in the last quarter. Simon Quick Advisors LLC lifted its stake in Abbott Laboratories by 4.0% in the 4th quarter. Simon Quick Advisors LLC now owns 3,302 shares of the healthcare product maker’s stock worth $287,000 after purchasing an additional 127 shares in the last quarter. RKL Wealth Management LLC lifted its stake in Abbott Laboratories by 3.5% in the 3rd quarter. RKL Wealth Management LLC now owns 3,757 shares of the healthcare product maker’s stock worth $316,000 after purchasing an additional 128 shares in the last quarter. Finally, Boltwood Capital Management lifted its stake in Abbott Laboratories by 0.5% in the 3rd quarter. Boltwood Capital Management now owns 27,789 shares of the healthcare product maker’s stock worth $2,325,000 after purchasing an additional 130 shares in the last quarter. 73.59% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have issued reports on ABT shares. ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Guggenheim cut shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, January 2nd. Evercore ISI cut shares of Abbott Laboratories from an “outperform” rating to an “in-line” rating in a research note on Thursday, January 2nd. Citigroup cut shares of Abbott Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, January 2nd. Finally, Credit Suisse Group increased their target price on shares of Abbott Laboratories from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $91.42.

In other news, SVP Randel William Woodgrift sold 21,000 shares of the stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $80.54, for a total value of $1,691,340.00. Following the transaction, the senior vice president now owns 68,562 shares of the company’s stock, valued at approximately $5,521,983.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is owned by corporate insiders.

Shares of NYSE:ABT opened at $85.74 on Wednesday. The company’s fifty day moving average price is $86.06 and its 200-day moving average price is $84.55. The firm has a market capitalization of $150.96 billion, a price-to-earnings ratio of 29.77, a PEG ratio of 2.16 and a beta of 1.12. Abbott Laboratories has a one year low of $68.36 and a one year high of $89.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 1.12.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $0.84 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.84. The firm had revenue of $8.08 billion for the quarter, compared to analyst estimates of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 3.24 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a $0.36 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.68%. Abbott Laboratories’s dividend payout ratio is presently 44.44%.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Article: Are analyst ratings accurate?

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.